Milestones and Key Events
Un-blinded rapid virologic response (RVR) and early virologic response (EVR) data from the on-going Phase 2b study of RG7227 plus SOC (un-boosted 12-week regimens)
Late Q1 or early Q2 2010 (updated guidance with additional data reported)
Initiation of INFORM-2 program (ritonavir-boosted RG7227 plus RG7128)
Q1 2010: Timing subject to change due to integration of new ritonavir boosting strategy
Initiation of longer duration DAA study to evaluate SVR (ritonavir boosted)
Q2 2010: Timing subject to change due to integration of new ritonavir boosting strategy
Initiation of Phase 2b study of ritonavir-boosted RG7227 plus SOC
Q3 2010 (new study)
Subscribe to our Free Newsletters!
Cachexia refers to severe muscle and fat loss, anorexia and marked weight loss due to an underlying ...
Exotropia or outward eye deviation is a form of squint. Proper evaluation and timely intervention ...
Glaucoma is a group of disorders involving the optic nerve, often associated with a rise in ...View All